AAA Deal Roundup: Quest to buy Haystack in $450m deal

Deal Roundup: Quest to buy Haystack in $450m deal

M&A

Medical lab operator Quest Diagnostics is acquiring Haystack Oncology, a cancer-focused blood diagnostics technology developer backed by corporates Bruker, Exact Sciences and Alexandria Real Estate Equities, for up to $450m. The deal, which is set to close in June, involves $300m in cash with the remainder dependent on Haystack’s test performance milestones. The company last raised funding in a $56m series A round in November 2022.

Funding

HPV-derived pre-cancerous lesion therapy developer Antiva Biosciences received $53m in series E funding from investors including internet technology conglomerate Alphabet’s GV unit. The round was led by MPM-BioImpact Capital and also featured Canaan Partners, Sofinnova Investments, Adjuvant Capital and Lumira Ventures.

CompanyCompany DescriptionSectorCountryRoundRound size ($m)Deal dateInvestors
EvommuneInflammatory disease treatment developerHealthcareUSB5026/04/2023Nan Fung (Pivotal BioVenture Partners); Arix Bioscience (co-lead), EQT Life Sciences (co-lead), SymBiosis (co-lead), Amplitude Ventures, Andera Partners
Kingstar Winning Software TechnologyHealthcare monitoring software subsidiary of Winning HealthHealthcareChinaC43.328/04/2023China Taiping Insurance Holdings (China Taiping Medical and Health Equity Investment Fund) (lead), China Electronics Corporation (SND Financial Holdings); Cathay Capital, Tiliang Investment Management
Therini BioInflammatory neurodegenerative and retinal disease treatment developerHealthcareUSA3627/04/2023Merck & Co (MRL Ventures Fund) (co-lead), Sanofi (Sanofi Ventures), Eli Lilly and Company; SV Health Investors (Dementia Discovery Fund/Impact Medicine Fund) (co-lead), Alzheimer’s Drug Discovery Foundation, Dolby Family Ventures, Foundation for a Better World
Pattern BioscienceAntibiotic resistance-focused diagnostics technology developerHealthcareUSC28.727/04/2023Illumina (Illumina Ventures) (lead); Omnimed Capital, Antimicrobial Resistance Action Fund, Daleshaw
BiomicaMicrobiome-based therapeutics developerHealthcareIsraelN/A2027/04/2023Evogene; Shanghai Healthcare Capital (lead)
DeepHowAI-powered workplace training platformServicesUSA1427/04/2023LG (LG Technology Ventures), Qualcomm (Qualcomm Ventures); Owl Ventures (lead), Sierra Ventures, Osage Venture Partners, Foothill Ventures
HivedZero-emissions parcel delivery serviceServicesUKA12.426/04/2023AP Moller-Maersk (Maersk Growth); Planet A Ventures (lead), Eka Ventures, Pale Blue Dot
WayhomeRent-to-buy home purchase finance serviceFinancialUKA9.926/04/2023Allianz (Allianz X) (lead); Augment Fintech, Love Ventures, Cur8 Capital, Volution
Iris Audio TechnologiesVoice isolation technology developerMediaUKA727/04/2023TAG Group; Puma Private Equity (lead), Ojjeh family, Toby Brzoznowski 
TemboDigital mortgage platformFinancialUKN/A6.227/04/2023Aviva (Aviva Ventures); Love Ventures, McPike Family Office, Ascension Ventures
IDPartnerDeveloper of privacy-preserving online identity verification tool ITUKSeed3.126/04/2023Circle (Circle Ventures); Abstract Ventures (lead), Foundation Capital, Firsthand Alliance, Correlation Ventures, Success Venture Partners, Aleo
VerteegoProvider of consumer business planning softwareITFranceN/A2.727/04/2023Finoli; Archipel Ventures, Supercapital, Holnest, BPIfrance, Kima Ventures, Charles Egly, Guillaume Princen, Loïc Villers, Etienne Besançon

By Angela Logan

Angela Logan is news and production editor at Global Venturing.